Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pediatric voriconazole study for invasive and esophageal candidiasis
2009-012848-16Phase 3Completed
- Sponsor
- Pfizer
- Start
- Feb 2010
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of voriconazole in invasive candidiasis, candidemia and Candida esophagitis, sponsored by Pfizer. Primary endpoint: Safety and tolerability of voriconazole. Started Feb 2010; status: completed.
02
Drugs
voriconazole
03
Conditions
invasive candidiasiscandidemiaCandida esophagitis
Beyond the preview
Go deeper on 2009-012848-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-012848-16.